Skip to main content

Biorem Inc.(BRM-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low2.900
Day High3.110
Open:2.910
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newswire.ca
Biorem Reports $65.3 Million Order Backlog
Newswire.ca
Biorem Reports Record Revenues and Earnings before tax for 2025
Newsfile
Upcoming Meeting Dates - April 20, 2026
Newswire.ca
Biorem Reports Record Order Backlog, - $11.3 Million of Revenues in the Quarter and Quarterly EPS of $0.07
Newswire.ca
Biorem Reports Second Quarter Results
PR Newswire
BIOREM Announces Approval of Normal Course Issuer Bid
AI-generated - The Globe and Mail
Biorem: Stocks Undervalued by Analyst Consensus on TSX-V (BRM)
PR Newswire
BIOREM Reports First Quarter Financial Results and Record $68 Million Order Backlog
AI-generated - The Globe and Mail
Biorem: Top 10 Undervalued Industrials Sector Stocks on TSX-V (BRM)
AI-generated - The Globe and Mail
Biorem: Top 10 Undervalued Industrials Sector Stocks on TSX-V (BRM)
Newswire.ca
Biorem Reports Record Revenues and Earnings before tax for 2024 and Again Reports Record Order Backlog
AI-generated - The Globe and Mail
Biorem: Stocks Undervalued by Analyst Consensus on TSX-V (BRM)
AI-generated - The Globe and Mail
Biorem: Top 10 Undervalued Industrials Sector Stocks on TSX-V (BRM)
AI-generated - The Globe and Mail
Biorem: Top 10 Undervalued Industrials Sector Stocks on TSX-V (BRM)
Newswire.ca
BIOREM Announces Orders Totalling $8 Million and Order Backlog of $60.5 Million
AI-generated - The Globe and Mail
Biorem: Top 10 Undervalued Industrials Sector Stocks on TSX-V (BRM)
Newswire.ca
BIOREM Announces New Orders Totalling $13 Million and Order Backlog of $58 Million
PR Newswire
Biorem Reports Record Quarterly Revenues and Earnings, - $14.9 Million of Revenues in the Quarter and Quarterly EPS of $0.14
Newswire.ca
Biorem Reports Record Quarterly Revenues and Earnings, - $14.9 Million of Revenues in the Quarter and Quarterly EPS of $0.14
Newswire.ca
Biorem Reports Second Quarter Results with 77% Increase in Year over Year Revenue and Record Order Backlog
AI-generated - The Globe and Mail
Biorem: Top 10 Undervalued Growth Stocks on TSX-V (BRM)
AI-generated - The Globe and Mail
Biorem: Top 10 Undervalued Industrials Sector Stocks on TSX-V (BRM)
Newswire.ca
Biorem Announces Stock Option Grant
Newswire.ca
BIOREM Reports Strong First Quarter Financial Results and Continued Growth in Order Backlog
Newswire.ca
Biorem Reports 2023 Financial Results including $0.14 earnings per share
Newswire.ca
Biorem Reports Third Quarter Results, Record Order Backlog and Quarterly EPS of $0.03
Newswire.ca
Biorem Reports Second Quarter Results and Record Order Backlog
Newswire.ca
Biorem Announces Stock Option Grant
Newswire.ca
BIOREM order backlog exceeds $50 million on strength of $11-million in new orders
PR Newswire
Biorem Reports First Quarter Financial Results
Newswire.ca
Biorem Reports Record 2022 Financial Results
Newswire.ca
Biorem Reports Third Quarter Results & Increases in Revenues and Earnings

Profile

Biorem Inc is an environmental biotechnology company. It is involved in the manufacturing of a comprehensive line of high efficiency air pollution control systems that are used to eliminate odorous and harmful contaminants. The company's products include Biofilters, Biogas Solutions, Multi-Stage Systems, Biotrickling filters, and services such as Media Sampling and Analysis, Biological processes and testing, Media replacements and Spare parts, and other related services. The company derives revenues from the sale of standard products, construction projects for specialized products, and services for repairs and maintenance. The group has a business presence in Canada, the United States, China and others, of which key revenue is derived from the United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.